Filing Details

Accession Number:
0001398344-25-010597
Form Type:
13G Filing
Publication Date:
2025-05-28 20:00:00
Filed By:
Hudson View Holdings LLC
Company:
Maravai Lifesciences Holdings Inc. (NASDAQ:MRVI)
Filing Date:
2025-05-29
SEC Url:
13G Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Beneficially Owned Number of Shares Beneficially Owned Number of Aggregate Shares Percent of Class
Hudson View Holdings LLC 0 4,866,400 3.38%
Hudson View Capital LLC 0 4,866,400 3.38%
JD Squared Holdings II LLC 0 2,000,000 1.39%
JD Squared Capital II LLC 0 2,000,000 1.39%
Stuart Feldman 0 6,866,400 4.77%
Matthew Barkoff 0 2,241,600 1.56%
Joshua Wool 0 320,000 0.22%
Filing





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)






SCHEDULE 13G




SCHEDULE 13G




SCHEDULE 13G




SCHEDULE 13G




SCHEDULE 13G




SCHEDULE 13G




SCHEDULE 13G




SCHEDULE 13G


 
Hudson View Holdings LLC
 
Signature:/s/ Jeffrey Goldberg
Name/Title:Authorized Signatory
Date:05/29/2025
 
Hudson View Capital LLC
 
Signature:/s/ Jeffrey Goldberg
Name/Title:Authorized Signatory
Date:05/29/2025
 
JD Squared Holdings II LLC
 
Signature:/s/ Jeffrey Goldberg
Name/Title:Authorized Signatory
Date:05/29/2025
 
JD Squared Capital II LLC
 
Signature:/s/ Jeffrey Goldberg
Name/Title:Authorized Signatory
Date:05/29/2025
 
Stuart Feldman
 
Signature:/s/ Joseph Brucchieri
Name/Title:Attorney-in-fact
Date:05/29/2025
 
Matthew Barkoff
 
Signature:/s/ Matthew Barkoff
Name/Title:Individual
Date:05/29/2025
 
Joshua Wool
 
Signature:/s/ Joshua Wool
Name/Title:Individual
Date:05/29/2025
Exhibit Information

99.1 Joint Filing Agreement 99.2 Power of Attorney (incorporated by reference to Exhibit 99.2 to the Schedule 13G in respect of Mural Oncology plc filed on May 14, 2025).